Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2009

01-05-2009 | Original Article

Comparison of subcutaneous and intraperitoneal injection of d-luciferin for in vivo bioluminescence imaging

Authors: Yusuke Inoue, Shigeru Kiryu, Kiyoko Izawa, Makoto Watanabe, Arinobu Tojo, Kuni Ohtomo

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2009

Login to get access

Abstract

Purpose

We compared subcutaneous (SC) injection and intraperitoneal (IP) injection of d-luciferin for in vivo bioluminescence imaging (BLI) to determine the utility of SC injection.

Methods

Mice bearing SC tumours stably expressing firefly luciferase underwent in vivo BLI using SC and IP injection of d-luciferin. BLI studies were repeated at an interval of 3 h using a given injection route to assess repeatability and using different injection routes to assess correlation. In mice bearing both SC and IP tumours, BLI was performed successively using intravenous (IV), SC, and IP injection of d-luciferin. Haematological malignancy model mice underwent BLI using SC and IP injection.

Results

In SC tumours, the peak time was slightly shorter and the peak signal was greater using SC injection than using IP injection. The repeatability of determining peak signals was comparable between the two injection routes, and a good correlation was observed between them. In mice bearing both SC and IP tumours, signals from IP tumours relative to those from SC tumours were much greater using IP injection than using IV or SC injection. In the haematological malignancy model, signals from the spleen relative to those from the bone marrow were greater using IP injection than using SC injection.

Conclusion

In addition to rare injection failure, the IP injection of d-luciferin led to the overestimation of signals from IP tissues. For BLI, SC injection was shown to be a convenient alternative to IP injection.
Literature
1.
go back to reference Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002;38:2128–36.PubMedCrossRef Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 2002;38:2128–36.PubMedCrossRef
2.
go back to reference Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000;2:41–52.PubMedCrossRef Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2000;2:41–52.PubMedCrossRef
3.
go back to reference Cao YA, Wagers AJ, Beilhack A, Dusich J, Bachmann MH, Negrin RS, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci USA 2004;101:221–6.PubMedCrossRef Cao YA, Wagers AJ, Beilhack A, Dusich J, Bachmann MH, Negrin RS, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci USA 2004;101:221–6.PubMedCrossRef
4.
go back to reference Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001;107:1293–301.PubMedCrossRef Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, et al. Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest 2001;107:1293–301.PubMedCrossRef
5.
go back to reference Hutchens M, Luker GD. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol 2007;9:2315–22.PubMedCrossRef Hutchens M, Luker GD. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol 2007;9:2315–22.PubMedCrossRef
6.
go back to reference Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002;8:891–7.PubMed Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002;8:891–7.PubMed
7.
go back to reference Carlsen H, Alexander G, Austenaa LM, Ebihara K, Blomhoff R. Molecular imaging of the transcription factor NF-kappaB, a primary regulator of stress response. Mutat Res 2004;551:199–211.PubMed Carlsen H, Alexander G, Austenaa LM, Ebihara K, Blomhoff R. Molecular imaging of the transcription factor NF-kappaB, a primary regulator of stress response. Mutat Res 2004;551:199–211.PubMed
8.
go back to reference Massoud TF, Paulmurugan R, De A, Ray P, Gambhir SS. Reporter gene imaging of protein-protein interactions in living subjects. Curr Opin Biotechnol 2007;18:31–7.PubMedCrossRef Massoud TF, Paulmurugan R, De A, Ray P, Gambhir SS. Reporter gene imaging of protein-protein interactions in living subjects. Curr Opin Biotechnol 2007;18:31–7.PubMedCrossRef
9.
go back to reference Edinger M, Hoffmann P, Contag CH, Negrin RS. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 2003;31:172–9.PubMedCrossRef Edinger M, Hoffmann P, Contag CH, Negrin RS. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 2003;31:172–9.PubMedCrossRef
10.
go back to reference Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol Imaging 2007;6:315–22.PubMed Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol Imaging 2007;6:315–22.PubMed
11.
go back to reference Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, Antich PP, et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 2004;3:117–24.PubMedCrossRef Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, Antich PP, et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 2004;3:117–24.PubMedCrossRef
12.
go back to reference Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008;35:999–1007.PubMedCrossRef Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008;35:999–1007.PubMedCrossRef
13.
go back to reference Lee KH, Byun SS, Paik JY, Lee SY, Song SH, Choe YS, et al. Cell uptake and tissue distribution of radioiodine labelled d-luciferin: implications for luciferase based gene imaging. Nucl Med Commun 2003;24:1003–9.PubMedCrossRef Lee KH, Byun SS, Paik JY, Lee SY, Song SH, Choe YS, et al. Cell uptake and tissue distribution of radioiodine labelled d-luciferin: implications for luciferase based gene imaging. Nucl Med Commun 2003;24:1003–9.PubMedCrossRef
14.
go back to reference Zeamari S, Rumping G, Floot B, Lyons S, Stewart FA. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer 2004;90:1259–64.PubMedCrossRef Zeamari S, Rumping G, Floot B, Lyons S, Stewart FA. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer 2004;90:1259–64.PubMedCrossRef
15.
go back to reference Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13:4209–17.PubMedCrossRef Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13:4209–17.PubMedCrossRef
16.
go back to reference Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, et al. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging. Eur J Nucl Med Mol Imaging 2007;34:841–9.PubMedCrossRef Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, et al. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging. Eur J Nucl Med Mol Imaging 2007;34:841–9.PubMedCrossRef
17.
go back to reference Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N, et al. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 2006;66:989–98.PubMedCrossRef Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N, et al. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 2006;66:989–98.PubMedCrossRef
18.
go back to reference Bryant MJ, Chuah TL, Luff J, Lavin MF, Walker DG. A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line. J Clin Neurosci 2008;15:545–51.PubMedCrossRef Bryant MJ, Chuah TL, Luff J, Lavin MF, Walker DG. A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line. J Clin Neurosci 2008;15:545–51.PubMedCrossRef
19.
go back to reference Zhang Y, Bressler JP, Neal J, Lal B, Bhang HE, Laterra J, et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 2007;67:9389–97.PubMedCrossRef Zhang Y, Bressler JP, Neal J, Lal B, Bhang HE, Laterra J, et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 2007;67:9389–97.PubMedCrossRef
20.
go back to reference Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607–14.PubMedCrossRef Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005;2:607–14.PubMedCrossRef
21.
go back to reference Inoue Y, Tojo A, Sekine R, Soda Y, Kobayashi S, Nomura A, et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 2006;33:557–65.PubMedCrossRef Inoue Y, Tojo A, Sekine R, Soda Y, Kobayashi S, Nomura A, et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 2006;33:557–65.PubMedCrossRef
22.
go back to reference Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85:1151–68.PubMed Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995;85:1151–68.PubMed
23.
go back to reference Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999;189:1399–412.PubMedCrossRef Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999;189:1399–412.PubMedCrossRef
24.
go back to reference Inoue Y, Izawa K, Tojo A, Nomura Y, Sekine R, Oyaizu N, et al. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. Exp Hematol 2007;35:407–15.PubMedCrossRef Inoue Y, Izawa K, Tojo A, Nomura Y, Sekine R, Oyaizu N, et al. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy. Exp Hematol 2007;35:407–15.PubMedCrossRef
25.
go back to reference Inoue Y, Izawa K, Kiryu S, Kobayashi S, Tojo A, Ohtomo K. Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. Exp Hematol 2008;36:1634–41.CrossRef Inoue Y, Izawa K, Kiryu S, Kobayashi S, Tojo A, Ohtomo K. Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. Exp Hematol 2008;36:1634–41.CrossRef
26.
go back to reference Wang W, El-Deiry WS. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2003;2:196–202.PubMed Wang W, El-Deiry WS. Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2003;2:196–202.PubMed
Metadata
Title
Comparison of subcutaneous and intraperitoneal injection of d-luciferin for in vivo bioluminescence imaging
Authors
Yusuke Inoue
Shigeru Kiryu
Kiyoko Izawa
Makoto Watanabe
Arinobu Tojo
Kuni Ohtomo
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-1022-8

Other articles of this Issue 5/2009

European Journal of Nuclear Medicine and Molecular Imaging 5/2009 Go to the issue